Investing.comDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 19:04:37·⟳ 抓取 19:10:13 +5m36s·⚡ 决策 10-08 19:11:43 +1m30s·19.2 天前
Editas Medicine 获澳大利亚批准启动 EDIT-401 治疗杂合子家族性高胆固醇血症的 I/II 期 Strive 试验
澳大利亚 CTN/伦理批准仅使资产从临床前推进到 I/II 期启动，属程序性质、预期内的早期里程碑；无人体疗效数据，初步安全性要到2027年一季度，对无营收的 Editas 短期基本面无可量化增量，盘前流动性极薄，缺乏短线正期望。
📄 原文Investing.com↗ 原文
Editas Medicine receives approval to start EDIT-401 trial in Australia
By Investing.com Advertisement Advertisement Editas Medicine receives approval to start EDIT-401 trial in Australia Com…
不做 Editas Medicine（EDIT.US）
澳大利亚 CTN/伦理批准是预期内、程序性的 I/II 期启动节点，无人体疗效与收入增量，初步数据需等到2027年一季度；盘前量极薄、无明确正期望，不追多。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
EDIT-401 获准在澳启动 I/II 期试验是温和正面的去风险事件，但仅为早期常规监管节点，无收入或人体疗效支撑；股价盘前几乎无量、未明显重定价，追多 edge 不足，建议不做。
🔎 新鲜度:最早出现 2026-10-08 · 扩散 low · price-in 风险 low ↗
关键理由
- 全资管线 EDIT-401 从临床前进入 I/II 期，临床前约90%降脂数据为平台提供概念验证
- 催化剂真实但预期差小，市场通常对 CTN 类常规节点反应有限
主要风险
- I 期在体基因编辑存在人体安全性/递送不确定性，初步数据2027年才出，短线易回落
- 若新西兰批准延迟、入组缓慢或现金消耗引发融资，股价承压
反向证据
- 做多前查反向 · 来源 kb_search · 影响 weakens
未在已处理事件库命中同催化；市值约4.2亿美元、无营收，公司无近期正向业绩或合作惊喜可放大此节点
检索:Editas EDIT-401 trial already disclosed Australia CTN milestone prior guidance
先例如何影响了这次决策
对本次决策的影响:早期常规 CTN 里程碑的基本面增量判断足以导向回避，未因缺少先例而强行 ENTER
方向:未构建对齐先例
涨幅量级:无法用先例校准幅度
形态:无可量化的见光死模式
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 15 ms
{"result": "search_processed_events:agent query=`edit-401 phase 1/2 heterozygous familial hypercholesterolemia australia tga clinical trial notification | editas in vivo gene editing ldlr australia new zealand trial | editas medi`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools HTTP · 8 ms
{ - stock_quote 成功 stock_tools HTTP · 527 ms
{ - normalize_ticker 成功 stock_tools HTTP · 12 ms
{
原文全文
展开原文 · 7,772 字
Editas Medicine receives approval to start EDIT-401 trial in Australia By Investing.com
Advertisement
Advertisement
Editas Medicine receives approval to start EDIT-401 trial in Australia
Company News
Published
Oct 08, 2026, 07:04 AM
Editas Medicine receives approval to start EDIT-401 trial in Australia
View all comments (0)
0
Editas Medicine receives approval to start EDIT-401 trial in Australia
View all comments (0)
0
© Reuters
In this article:
EDIT
+
0.73%
CAMBRIDGE, Mass. -
Editas Medicine
, Inc. (
NASDAQ:EDIT
) announced Thursday it received approval to begin its Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia in Australia, according to a press release statement.
The trial received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia’s Therapeutic Goods Administration. The company has also submitted the trial for review in New Zealand, with patients in both countries eligible to enroll if New Zealand approval is granted.
EDIT-401 is an experimental in vivo gene editing medicine designed to treat hyperlipidemia by editing the LDLR gene to increase LDLR protein expression and reduce LDL-cholesterol levels. In preclinical studies, EDIT-401 demonstrated a mean reduction of approximately 90 percent or greater in multiple atherogenic lipoproteins, including LDL-C, Lp(a), and ApoB in non-human primates.
The company said new preclinical data showed an LDL-C reduction of approximately 90 percent was maintained over 10 months in an ongoing study in non-human primates. This data will be presented at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago.
The Strive trial will evaluate the safety, tolerability, and efficacy of a single dose of EDIT-401. Part 1 is a single ascending dose, dose-finding, open-label trial, while Part 2 will be a single-dose randomized, placebo-controlled expansion study.
Editas has selected five clinical trial sites across Australia and New Zealand. The company expects to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027. The company plans to complete enrollment in Part 1 with topline safety and efficacy data results available later in 2027.
Heterozygous Familial Hypercholesterolemia is an inherited genetic disorder that leads to significantly elevated LDL-C levels from an early age. An estimated 1.2 million people in the United States are living with HeFH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Editas Medicine receives approval to start EDIT-401 trial in Australia
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,658.00
-521.2
-1.02%
US 500
7,755.90
-45.8
-0.59%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.98
+0.90
+5.97%
Dollar Index
102.225
+0.212
+0.21%
Crude Oil WTI Futures
92.76
+4.48
+5.07%
Brent Oil Futures
105.43
+5.23
+5.22%
Natural Gas Futures
3.252
+0.049
+1.53%
Gold Futures
4,139.12
-1.58
-0.04%
Silver Futures
58.88
-1.414
-2.35%
Copper Futures
6.6288
-0.0207
-0.31%
US Soybeans Futures
1,295.25
-1.75
-0.13%
U.S. 10Y
5.355
+0.077
+1.46%
U.S. 30Y
5.725
+0.064
+1.13%
U.S. 5Y
5.091
+0.070
+1.39%
U.S. 3M
4.143
+0.002
+0.05%
US 10Y T-Note Futures
104.05
-0.44
-0.42%
Euro Bund Futures
120.40
-0.42
-0.34%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Samsung shares fall as record Q3 profit misses lofty expectations
By Investing.co
...
Oct 08, 2026
Fed minutes show most policymakers see another rate hike by year end
By Investing.co
...
Oct 07, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Gold Rebounds, but Strong Dollar, Rising Yields Keep Downside Risks in Play
By Fawad Razaqz
...
Oct 05, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
Advertisement
Advertisement
Editas Medicine receives approval to start EDIT-401 trial in Australia
Company News
Published
Oct 08, 2026, 07:04 AM
Editas Medicine receives approval to start EDIT-401 trial in Australia
View all comments (0)
0
Editas Medicine receives approval to start EDIT-401 trial in Australia
View all comments (0)
0
© Reuters
In this article:
EDIT
+
0.73%
CAMBRIDGE, Mass. -
Editas Medicine
, Inc. (
NASDAQ:EDIT
) announced Thursday it received approval to begin its Phase 1/2 Strive clinical trial of EDIT-401 in patients with Heterozygous Familial Hypercholesterolemia in Australia, according to a press release statement.
The trial received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia’s Therapeutic Goods Administration. The company has also submitted the trial for review in New Zealand, with patients in both countries eligible to enroll if New Zealand approval is granted.
EDIT-401 is an experimental in vivo gene editing medicine designed to treat hyperlipidemia by editing the LDLR gene to increase LDLR protein expression and reduce LDL-cholesterol levels. In preclinical studies, EDIT-401 demonstrated a mean reduction of approximately 90 percent or greater in multiple atherogenic lipoproteins, including LDL-C, Lp(a), and ApoB in non-human primates.
The company said new preclinical data showed an LDL-C reduction of approximately 90 percent was maintained over 10 months in an ongoing study in non-human primates. This data will be presented at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago.
The Strive trial will evaluate the safety, tolerability, and efficacy of a single dose of EDIT-401. Part 1 is a single ascending dose, dose-finding, open-label trial, while Part 2 will be a single-dose randomized, placebo-controlled expansion study.
Editas has selected five clinical trial sites across Australia and New Zealand. The company expects to begin patient dosing this year and report initial safety and tolerability data in the first quarter of 2027. The company plans to complete enrollment in Part 1 with topline safety and efficacy data results available later in 2027.
Heterozygous Familial Hypercholesterolemia is an inherited genetic disorder that leads to significantly elevated LDL-C levels from an early age. An estimated 1.2 million people in the United States are living with HeFH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Editas Medicine receives approval to start EDIT-401 trial in Australia
View all comments (0)
0
Latest comments
Post
Comment Guidelines
Trade With A Regulated Broker
Indices
Commodities
Bonds
Stocks
US 30
50,658.00
-521.2
-1.02%
US 500
7,755.90
-45.8
-0.59%
Dow Jones
51,179.87
-341.41
-0.66%
S&P 500
7,801.77
-17.16
-0.22%
Nasdaq
27,538.69
-61.19
-0.22%
S&P 500 VIX
15.98
+0.90
+5.97%
Dollar Index
102.225
+0.212
+0.21%
Crude Oil WTI Futures
92.76
+4.48
+5.07%
Brent Oil Futures
105.43
+5.23
+5.22%
Natural Gas Futures
3.252
+0.049
+1.53%
Gold Futures
4,139.12
-1.58
-0.04%
Silver Futures
58.88
-1.414
-2.35%
Copper Futures
6.6288
-0.0207
-0.31%
US Soybeans Futures
1,295.25
-1.75
-0.13%
U.S. 10Y
5.355
+0.077
+1.46%
U.S. 30Y
5.725
+0.064
+1.13%
U.S. 5Y
5.091
+0.070
+1.39%
U.S. 3M
4.143
+0.002
+0.05%
US 10Y T-Note Futures
104.05
-0.44
-0.42%
Euro Bund Futures
120.40
-0.42
-0.34%
10-2 Yield Spread
31.32
+4.15
+15.27%
AAPL
336.67
+3.04
+0.91%
NVDA
237.47
-1.77
-0.74%
GOOGL
350.50
+2.82
+0.81%
TSLA
377.81
-2.87
-0.75%
AMZN
259.92
+3.63
+1.42%
NFLX
69.70
+1.01
+1.47%
META
721.31
-17.57
-2.38%
Advertisement
Most Popular Articles
News
Analysis
Oil prices surge amid Mideast shipping attacks, U.S. Gulf coast disruptions
By Investing.co
...
Oct 08, 2026
AI debt deal wave reports; Applied Digital reports - what’s moving markets
By Investing.co
...
Oct 08, 2026
Wall Street posts first red session of October a day after notching a record close
By Investing.co
...
Oct 08, 2026
Samsung shares fall as record Q3 profit misses lofty expectations
By Investing.co
...
Oct 08, 2026
Fed minutes show most policymakers see another rate hike by year end
By Investing.co
...
Oct 07, 2026
Micron Has Surged on the AI Boom - Is It Still a Buy?
By Antonio Rodr
...
Oct 06, 2026
9 Fundamentally Strong Stocks to Watch as Q3 Earnings Get Underway
By David Wagner
Oct 08, 2026
Nvidia Hits Another New High: Key Breakout and Retracement Targets to Watch
By Lee Yang
Oct 06, 2026
Worried Consumers Keep Spending: Here’s Why
By Michael Lebo
...
Oct 07, 2026
Gold Rebounds, but Strong Dollar, Rising Yields Keep Downside Risks in Play
By Fawad Razaqz
...
Oct 05, 2026
More News
Market Movers
Most Active
Gainers %
Losers %
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
SPCX
167.60
-2.51%
77.47M
AMD
645.86
-0.55%
18.56M
AAPL
336.67
+0.91%
34.15M
TSLA
377.81
-0.75%
25.59M
Name
Last
Chg. %
Vol.
NRG
108.61
+4.84%
5.39M
MRNA
196.48
+4.81%
14.64M
MU
1,088.00
+4.06%
30.86M
CTVA
14.45
+3.88%
41.33M
VST
166.72
+3.88%
12.01M
SMCI
44.94
+3.41%
40.54M
NTAP
235.77
+3.20%
3.00M
Name
Last
Chg. %
Vol.
MSTR
153.37
-6.79%
21.67M
SKYD
8.89
-6.72%
43.30M
CAT
813.83
-5.75%
3.34M
MHK
119.18
-5.45%
1.70M
NBIS
237.15
-5.09%
18.05M
CRWD
265.44
-4.81%
8.81M
BLDR
53.55
-4.75%
2.36M
Advertisement
Trending Stocks
Name
Last
Chg. %
Vol.
MU
1,088.00
+4.06%
30.86M
SPCX
167.60
-2.51%
77.47M
NVDA
237.47
-0.74%
81.77M
SNDK
1,692.42
+1.92%
9.17M
APLD
23.810
-6.04%
48.76M
Show more
Advertisement
ProPicks AI
AI-powered
stock picks
with a proven track record to
beat the S&P 500
.
Tech Titans
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Top Value Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best of Buffett
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Energy Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Financial Fortresses
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Quality Compounders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Small-Cap Sprinters
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Healthcare Heroes
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Beat the S&P 500
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Dominate the Dow
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mid-Cap Movers
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Mexican Stock Exchange Leaders
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Best Brazilian Stocks
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Italian Market Elite
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Alpha Germany Select
Stocks in this Strategy
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
aaaa aaaaa aaaa a
Unlock Strategy
Comments
Post
Comment Guidelines
Tools
Calendars
Economic Calendar
Earnings Calendar
Holiday Calendar
US Economy
Fed Rate Monitor Tool
US Treasury Yield Curve
More Tools
Stock Screener
Currency Converter
Markets
Ask WarrenAI
Stocks Picked by AI
Watchlist
Alerts
Top Brokers
Breaking News
Tools
Install Our App
Scan QR code to install app
Follow us
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。